Jpmorgan Chase & CO Indaptus Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 19 shares of INDP stock, worth $21. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19
Previous 15
26.67%
Holding current value
$21
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding INDP
# of Institutions
19Shares Held
605KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA256KShares$284,4540.0% of portfolio
-
Investment House LLC Las Vegas, NV100KShares$110,9730.01% of portfolio
-
Geode Capital Management, LLC Boston, MA73.1KShares$81,1730.0% of portfolio
-
Strategy Asset Managers LLC45.3KShares$50,3220.01% of portfolio
-
Pine Valley Investments LTD Liability CO Marlton, NJ44.1KShares$48,9340.01% of portfolio
About Indaptus Therapeutics, Inc.
- Ticker INDP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,258,600
- Market Cap $9.17M
- Description
- Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...